Targeted therapy in gynecologic cancers: Ready for prime time?

International Journal of Gynecology and Obstetrics

Volumn 131, Issue , 2015, Pages S150-S152

  Seoud, Muhieddine ^a   Lundqvist, Elisabeth Åvall ^b   Fujiwara, Keiichi ^c  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b LINKÖPING UNIVERSITY   (Sweden)

^c SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CAPILLARY DENSITY; DOSE DENSIFICATION; FEMALE; FEMALE GENITAL TRACT CANCER; HUMAN; MAINTENANCE THERAPY; MOLECULARLY TARGETED THERAPY; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR MICROENVIRONMENT; UTERINE CERVIX CANCER; CANCER STAGING; DRUG DESIGN; GENITAL NEOPLASMS, FEMALE; OVARIAN NEOPLASMS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84944072329     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1016/j.ijgo.2015.06.012     Document Type: Article

References (44)

1. International Agency on Cancer research Press release No. 233. Latest world cancer statistics. Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed Published December 2013 http://www.iarc.fr/en/media-centre/pr/2013/pdfs/pr223-E.pdf
2. K.S. Tewari Patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel Clin. Ovarian Cancer 4 2 2011 90 93
3. K.S. Tewari A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: commentary on Gynecologic Oncology Group protocol 204 Am J Hematol Oncol 9 2010 31 34
4. D.M. McDonald, and P. Baluk Significance of blood vessel leakiness in cancer Cancer Res 62 18 2002 5381 5385
5. R.A. Burger, M.F. Brady, M.A. Bookman, G.F. Fleming, B.J. Monk, H. Huang, and et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
6. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, G. Kristensen, and et al. A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 26 2011 2484 2496
7. C. Aghajanian, S.V. Blank, B.A. Goff, P.L. Judson, M.G. Teneriello, A. Husain, and et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 17 2012 2039 2045
8. E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, G. Kristensen, and et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial J Clin Oncol 32 13 2014 1302 1308
9. C. Gourley, A. McCavigan, T. Perren, J. Paul, C. Ogilvie Michie, M. Churchman, and et al. Molecular subgroup of high grade ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Presented at the 2014 ASCO Annual Meeting J Clin Oncol 32 2014 5s Abstract 5502
10. B.J. Winterhoff, S. Kommoss, A.L. Oberg, C. Wang, S.M. Riska, and et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. Presented at the 2014 ASCO Annual Meeting J Clin Oncol 32 2014 5s Abstract 5509
11. M. Friedlander, K.C. Hancock, D. Rischin, M.J. Messing, C.A. Stringer, G.M. Matthys, and et al. A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Gynecol Oncol 119 1 2010 32 37
12. U.A. Matulonis, S. Berlin, P. Ivy, K. Tyburski, C. Krasner, C. Zarwan, and et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 33 2009 5601 5606
13. J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, and et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol 15 8 2014 852 861
14. V. Lavoué, A. Thédrez, J. Levêque, F. Foucher, S. Henno, V. Jauffret, and et al. Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer J Transl Med 11 2013 147
15. M. Mazzoletti, and M. Broggini PI3K/AKT/mTOR inhibitors in ovarian cancer Curr Med Chem 17 36 2010 4433 4447
16. C.R. Miller, K.E. Oliver, and J.H. Farley MEK1/2 inhibitors in the treatment of gynecologic malignancies Gynecol Oncol 133 1 2014 128 137
17. X. Tang, Q. Zhang, J. Nishitani, J. Brown, S. Shi, and A.D. Le Overexpression of human papillomavirus type 16 oncoproteins enhances hypoxia-inducible factor 1 alpha protein accumulation and vascular endothelial growth factor expression in human cervical carcinoma cells Clin Cancer Res 13 9 2007 2568 2576
18. D.W. Leung, G. Cachianes, W.J. Kuang, D.V. Goeddel, and N. Ferrara Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 4935 1989 1306 1309
19. B.J. Monk, M.W. Sill, R.A. Burger, H.J. Gray, T.E. Buekers, and L.D. Roman Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study J Clin Oncol 27 7 2009 1069 1074
20. K.S. Tewari, M.W. Sill, H.J. Long 3rd, R.T. Penson, H. Huang, L.M. Ramondetta, and et al. Improved survival with bevacizumab in advanced cervical cancer N Engl J Med 370 8 2014 734 743
21. B.J. Monk, L. Mas Lopez, J.J. Zarba, A. Oaknin, C. Tarpin, W. Termrungruanglert, and et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer J Clin Oncol 28 22 2010 3562 3569
22. Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 201;8:CD003915.
23. J.T. Thigpen, M.F. Brady, H.D. Homesley, J. Malfetano, B. DuBeshter, R.A. Burger, and et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 22 19 2004 3902 3908
24. T. Thigpen, M.F. Brady, H.D. Homesley, J.T. Soper, and J. Bell Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study J Clin Oncol 19 2 2001 364 367
25. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 9484 2005 491 505
26. A.A. Kamat, W.M. Merritt, D. Coffey, Y.G. Lin, P.R. Patel, R. Broaddus, and et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer Clin Cancer Res 13 24 2007 7487 7495
27. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, P.G. Rose, and et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a GOG study J Clin Oncol 29 16 2011 2259 2265
28. F. Zagouri, G. Bozas, E. Kafantari, M. Tsiatas, N. Nikitas, M.A. Dimopoulos, and et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet Gynecol Int 2010 2010 749579
29. R.L. Coleman, M.W. Sill, H.A. Lankes, A.N. Fader, N.J. Finkler, J.S. Hoffman, and et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study Gynecol Oncol 127 3 2012 538 543
30. D.S. McMeekin, M.W. Sill, D. Benbrook, K.M. Darcy, D.J. Stearns-Kurosawa, L. Eaton, and et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study Gynecol Oncol 105 2 2007 508 516
31. K.K. Leslie, M.W. Sill, E. Fischer, K.M. Darcy, R.S. Mannel, K.S. Tewari, and et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study Gynecol Oncol 129 3 2013 486 494
32. K.V. Jasas, A. Fyles, L. Elit, P.J. Hoskins, J. Biagi, J. Dubuc-Lissoir, and et al. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-1. 2004 ASCO Annual Meeting Proceedings J Clin Oncol 22 14s 2004 Abstract 5019
33. K. Takahashi, Y. Saga, H. Mizukami, Y. Takei, S. Machida, H. Fujiwara, and et al. Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival Int J Oncol 35 4 2009 725 729
34. G.F. Fleming, M.W. Sill, K.M. Darcy, D.S. McMeekin, J.T. Thigpen, L.M. Adler, and et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 1 2010 15 20
35. A.D. Santin Letter to the Editor referring to the manuscript entitled: "Phase II trial of trastuzumab in women with advanced or recurrent HER2-positive endometrial carcinoma: a Gynecologic Oncology Group Study" recently reported by Fleming et al., (Gynecol Oncol., 116; 15-20;2010) Gynecol Oncol 118 1 2010 95 96 author reply 96-97
36. K.S. Elsahwi, and A.D. Santin erbB2 overexpression in uterine serous cancer: a molecular target for trastuzumab therapy Obstet Gynecol Int 2011 2011 128295
37. A.M. Oza, L. Elit, J. Biagi, W. Chapman, M. Tsao, D. Hedley, and et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160. 2006 ASCO Annual Meeting Proceedings J Clin Oncol 24 18s 2006 Abstract 3003
38. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, D.M. Provencher, and et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 24 2011 3278 3285
39. H.S. Nimeiri, A.M. Oza, R.J. Morgan, D. Huo, L. Elit, J.A. Knost, and et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 117 1 2010 37 40
40. N. Takai, J.C. Desmond, T. Kumagai, D. Gui, J.W. Said, S. Whittaker, and et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells Clin Cancer Res 10 3 2004 1141 1149
41. T. Tsuruta, K. Kozaki, A. Uesugi, M. Furuta, A. Hirasawa, I. Imoto, and et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer Cancer Res 71 20 2011 6450 6462
42. C. Trope, J.E. Johnsson, E. Simonsen, H. Christiansen, E. Cavallin-Stahl, and G. Horvath Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin Am J Obstet Gynecol 149 4 1984 379 381
43. T. Akram, P. Maseelall, and J. Fanning Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer Am J Obstet Gynecol 192 5 2005 1365 1367
44. C.M. Michener, G. Peterson, B. Kulp, K.D. Webster, and M. Markman Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma J Cancer Res Clin Oncol 131 9 2005 581 584